BIO CEO & Investor Conference 2009 Presenter Profiles

NEW YORK--(BUSINESS WIRE)--BIO CEO & Investor Conference 2009 takes place February 09, 2009 - February 10, 2009 at the Waldorf-Astoria in New York City.

Business Wire is the official news wire for the BIO CEO & Investor Conference 2009. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Listed below are BIO CEO & Investor Conference 2009 presenter profiles.

Company:	Acorda Therapeutics, Inc.
Ticker Symbol & Exchange:	ACOR / NASDAQ
Investor Relations Contact:	Jeff Macdonald
Investor Relations Contact Phone:	914-347-4300 ext. 232
Web:	www.acorda.com
Date of Presentation:	Monday, February 09, 2009
Acorda Therapeutics’ mission is to develop and market therapies to restore neurological function in people with spinal cord injury, multiple sclerosis and related conditions of the nervous system. Acorda’s marketed products include Zanaflex Capsules® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets for the management of spasticity. Acorda recently completed a Phase 3 clinical study of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with all types of MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Company:	Allon Therapeutics Inc.
Ticker Symbol & Exchange:	TSX:NPC
Investor Relations Contact:	Aaron Keay
Investor Relations Contact Phone:	D: (604) 742-2540, C: (604) 323-6911
Web:	www.allontherapeutics.com
Date of Presentation:	2/9/2009
Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon’s drug AL-108 has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment.
Company:	Allos Therapeutics, Inc
Ticker Symbol & Exchange:	ALTH
Investor Relations Contact:	Heather Rowe
Investor Relations Contact Phone:	720.560.0932
Web:	www.allos.com
Date of Presentation:	Feb. 9, 2009
Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company reported top line results from PROPEL in December 2008. Following review of the final results of the trial, the Company intends to submit a New Drug Application (NDA) for pralatrexate for the treatment of patients with relapsed or refractory PTCL in the first half of 2009. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment (SPA) process.
Company:	Amsterdam Molecular Therapeutics (AMT)
Ticker Symbol & Exchange:	AMT Euronext
Investor Relations Contact:	Rob Janssen
Investor Relations Contact Phone:	+31 6 54 70 88 65
Web:	www.amtbiopharma.com
Date of Presentation:	February 10, 2009, 2.15 p.m.
AMT is a world leader in gene therapy focused at serious, debilitating (orphan) diseases with a major medical need for treatment. The company has a well-filled, proprietary R&D pipeline with its lead product, Glybera®, close to market. AMT is a fully integrated biopharma company with its own GMP manufacturing system capable of producing large amounts of therapeutic product in a cost-effective and flexible way. AMT's pipeline covers metabolic, liver and blood coagulation diseases as well as diseases of the nervous system and the eye.
AMT employs a staff of 100 highly educated people with scientific and industrial experience.
Company:	AVANIR Pharmaceuticals
Ticker Symbol & Exchange:	AVNR / NASDAQ
Investor Relations Contact:	Eric Benevich
Investor Relations Contact Phone:	(949)389-6700
Web:	www.avanir.com
Date of Presentation:	February 10, 2009 at 9:30am ET
AVANIR Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for CNS disorders. AVANIR's lead product candidate, Zenvia™, is in Phase III development for two indications; pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. The Company is currently conducting a confirmatory Phase III trial with Zenvia in the treatment of PBA and is also in discussions with the U.S. Food and Drug Administration regarding a Special Protocol Assessment agreement for the next Phase III study of Zenvia in DPN pain. Please review AVANIR's website or SEC filings for information regarding risks and uncertainties affecting the Company.
Company:	BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	BPAX: NASDAQ
Investor Relations Contact:	Phillip Donenberg
Investor Relations Contact Phone:	847-478-0500 ext 100
Web:	www.biosantepharma.com
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Company:	Cyclacel Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	CYCC
Investor Relations Contact:	Corey Sohmer
Investor Relations Contact Phone:	908-517-7330
Web:	www.cyclacel.com
Date of Presentation:	2/9/2009
Cyclacel is a biopharmaceutical business dedicated to discovery, development and commercialization of novel, targeted drugs to treat cancer and other serious disorders. Three orally-available drugs are in clinical development: sapacitabine, in Phase 2 for the treatment of elderly acute myeloid leukemia, myelodysplastic syndromes, cutaneous T-cell lymphoma and non-small cell lung cancer; seliciclib, in Phase 2 for the treatment of non-small cell lung and nasopharyngeal cancers; and CYC116, in Phase 1 for solid tumors. Cyclacel's ALIGN subsidiary sells three products in the US: Xclair® Cream for radiation dermatitis and Numoisyn® Liquid and Lozenges for xerostomia.
Company:	Depomed, Inc.
Ticker Symbol & Exchange:	Nasdaq: DEPO
Investor Relations Contact:	Sheilah Serradell
Investor Relations Contact Phone:	650.462.5900
Web:	http://www.depomedinc.com/
Date of Presentation:	February 10, 2009 at 2:15pm ET
Depomed, Inc. is a specialty pharmaceutical company with a proven, proprietary AcuFormTM gastric retentive drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to absorption sites in the upper gastrointestinal tract. Benefits include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Depomed has two marketed products – GLUMETZA® for adults with type 2 diabetes and Proquin® XR for the once-daily treatment of uncomplicated urinary tract infections. Depomed has two phase 3 development programs including DM-1796 for the treatment of neuropathic pain, which has been licensed to Solvay Pharmaceuticals, and DM-5689 for menopausal hot flashes.
Company:	GeoVax Labs, Inc.
Ticker Symbol & Exchange:	(OTC BB: GOVX)
Investor Relations Contact:	Tim Grace
Investor Relations Contact Phone:	(312) 640-6667
Web:	www.geovax.com
Date of Presentation:	Feb. 10, 11:00 a.m.
GeoVax Labs, Inc. (OTC BB: GOVX), is a clinical stage biotechnology company, established to develop, manufacture, and commercialize human vaccines for HIV-1/AIDS. GeoVax's AIDS vaccine technology is designed for use in uninfected people to protect from contracting HIV-1/AIDS. The vaccines also may be effective as a treatment to reduce the need for drugs in already infected people. GeoVax's vaccines were developed at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax. Clinical trials, financed and conducted by the HIV Vaccine Trials Network (HVTN), are currently entering phase 2a.
Company:	Inspire Pharmaceuticals
Ticker Symbol & Exchange:	ISPH
Investor Relations Contact:	Jenny Kobin, VP, IR
Investor Relations Contact Phone:	919 941-9777, ext. 219
Web:	www.inspirepharm.com
Date of Presentation:	2/10/2009
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire is currently developing products for dry eye, cystic fibrosis and glaucoma. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis and Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis. Elestat is a registered trademark owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Company:	NPS Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	NPSP - NASDAQ
Investor Relations Contact:	Susan Mesco
Investor Relations Contact Phone:	908-450-5516
Web:	www.npsp.com
Date of Presentation:	2/10/2009
NPS Pharmaceuticals is developing new treatment options for rare gastrointestinal and endocrine disorders with high unmet medical needs. The company is currently advancing two late-stage programs. Teduglutide, a proprietary analog of GLP-2, is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome as GATTEX and in preclinical development for gastrointestinal mucositis and pediatric gastrointestinal conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Ortho-McNeil and Nycomed.
Company:	StemCells, Inc.
Ticker Symbol & Exchange:	Nasdaq GM: STEM
Investor Relations Contact:	Rodney Young
Investor Relations Contact Phone:	650 475 3100 x105
Web:	www.stemcellsinc.com
Date of Presentation:	2/10/2009
StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. StemCells has completed a Phase I clinical trial of its HuCNS SC® product candidate (purified human neural stem cells) for a fatal neurodegenerative disease, and has FDA approval to initiate a second Phase I trial for a fatal myelination disorder in the brain. The Company is at the preclinical stage for additional CNS indications, including retinal disorders and spinal cord injury. StemCells has also identified human liver engrafting cells (hLEC), which are in preclinical development.
Company:	ThromboGenics NV
Ticker Symbol & Exchange:	THR
Investor Relations Contact:	Stuart Laermer
Investor Relations Contact Phone:	+1 (212) 201-0920
Web:	www.thrombogenics.com
Date of Presentation:	February 9 at 2:15 pm
ThromboGenics is focused on discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company’s lead product Microplasmin is in Phase III for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II for additional vitreoretinal indications, and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics, including TB-402 (anti-Factor VIII), a long-acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.
ThromboGenics is headquartered in Leuven, Belgium, with subsidiaries in Ireland and New York. The Company is listed on Euronext under the symbol THR.

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.